So Yeon Kim, MD
Medical Oncology · North Haven, CTNPI 1760831408
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,844 of the $13,285 with a category attached, or 81.6%. 15 manufacturers reported payments, led by Boehringer Ingelheim at 38.2% of the total. 2025 is the largest year on record at $5,196, more than ten times the $110 reported in 2019.
Across 29 payments — averaging $458.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$5K
- Amgen$4K
- Genentech USA, Inc.$2K
- Sanofi$592
- Rigel Pharmaceuticals, Inc.$231
- Servier Pharmaceuticals LLC$225
- plus $1K from 9 others
Across 260 payments — averaging $10,386 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- Genmab A/s$382K
- Genentech, Inc.$302K
- Pfizer$260K
- Boehringer Ingelheim$246K
- E.r. Squibb & Sons, L.L.C.$135K
- plus $313K from 7 others
What the payments were for
- Consulting fees$10,84482%
- Food & beverage$2,26217%
- Education$1791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $5,075 |
| Amgen | 2 | $3,894 |
| Genentech USA, Inc. | 5 | $2,247 |
| Sanofi | 5 | $592 |
| Rigel Pharmaceuticals, Inc. | 2 | $231 |
| Servier Pharmaceuticals LLC | 2 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $202 |
| Exelixis Inc. | 1 | $162 |
| GSK | 1 | $125 |
| AstraZeneca | 2 | $121 |
| Genentech, Inc. | 2 | $118 |
| Gilead | 1 | $100 |
| Astellas Pharma US Inc | 1 | $99 |
| Foundation Medicine, Inc. | 1 | $82 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,285 in reported general payments places this provider in the 65th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $10,477 |
| Prochlorperazine Maleate | 15 | $254 |
| Dexamethasone | 13 | $184 |
| Prednisone | 22 | $88 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in North Haven
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Joseph McLaughlinManchester$200K
- Francine FossNew Haven$193K
- William OhGreenwich$162K
- Anne ChiangNew Haven$158K
- Mario SznolNew Haven$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.